Evolution of the measurement of quality of life in migraine

Neurology

Volumn 48, Issue 3 SUPPL. 3, 1997, Pages

  Solomon, Glen D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HEADACHE; HUMAN; MIGRAINE; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SOCIAL STATUS; WELLBEING;

EID: 0030936147     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.48.3_suppl_3.10s     Document Type: Article

References (33)

1. Jhingran P, Cady RK, Rubino J, et al. Improvements in health related quality of life with sumatriptan treatment for migraine. J Fam Pract 1996;42:36-42.
2. Kaa KA, Carlson JA, Osterhaus JT. Emergency department resource use by patients with migraine and asthma in a health maintenance organization. Ann Pharmacother 1995;29: 251-256.
3. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. JAMA 1992;267:64-69.
4. Headache Classification of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988; 81(suppl 7):1-96.
5. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Industries Study. Headache 1993;33:29-35.
6. Smith RC. Impact of migraine on the family. Headache 1996; 36:278.
7. Edmeads J, Findlay H, Tugwell P, et al. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993;20:131-137.
8. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 1989;262:907-913.
9. Solomon GD, Skobieranda FG, Gragg LA. Quality of life and well being of headache patients: measurement by the Medical Outcomes Study instrument. Headache 1993;33:351-358.
10. Solomon GD, Skobieranda FG, Gragg LA. Does quality of life differ among headache diagnoses? Analysis using the Medical Outcomes Study instrument. Headache 1994;34:143-147.
11. Skobieranda FG, Solomon GD, Gragg LA. Quality of life changes in headache patients following six months of outpatient treatment: use of the Medical Outcomes Study instrument [abstract]. Headache 1993;33:283.
12. Osterhaus JT, Townsend RJ. The quality of life of migraineurs: a cross sectional profile [abstract]. Cephalalgia 1991;11(suppl 11):103-104.
13. Miller DW, Osterhaus JT, Hirsh JD, et al. Quality of life assessment among migraineurs treated with sumatriptan: preliminary findings [abstract]. Headache 1993;33:278.
14. Tarlov AR, Ware JE, Greenfield S, et al. The Medical Outcomes Study. An application of methods for monitoring the results of medical care. JAMA 1989;262:925-930.
15. Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988;26:724-735.
16. McHorney CA, Ware JE, Raczek AK. The MOS 36-item short form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-263.
17. Dahlöf C, Dimenas E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995;15:31-36.
18. Osterhaus JT, Townsend RJ, Gandek B, et al. Measuring the functional status and well-being of patients with migraine headache. Headache 1994;34:337-343.
19. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989;262:914-919.
20. Osterhaus JT, Miller DW. The burden of migraine [abstract]. Headache 1993;33:279.
21. Dahlöf C, Björkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia 1993; 13:117-123.
22. Dahlöf C. Flunarizine versus long-acting propranolol in the prophylactic treatment of migraine: a double blind parellel group study. In: Rose FC, ed. New advances in headache research. London: Smith-Gordon, 1989:281-289.
23. Solomon GD, Kunkel RS. Long-term use of flurbiprofen in migraine prophylaxis [abstract]. Headache 1992;32:269-270.
24. Solomon GD, Nielson K, Miller D. The effects of sumatriptan on migraine: health related quality of life. Med Interface 1995; 8:134-141.
25. Solomon GD, Skobieranda FG, Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache 1995;35:449-454.
26. Beall D, Cohen J, Miller D, et al. An interim analysis of the use of subcutaneous sumatriptan in a managed care setting: effects on health-related quality of life, impact on health care resource use, and clinical efficacy. Pharmacotherapy 1995;15: 385.
27. Adelman J, Sharfman M, Johnson R, et al. Impact of oral sumatriptan on health-related quality of life and productivity in health care professionals with migraine: an interim analysis. Pharmacotherapy 1995;15:387.
28. Bullinger M, Bruggenjurgen B. Quality of life assessment among migraineurs under current treatment and after three months treatment with sumatriptan. Poster presented at the European Federation of Neurological Societies. Berlin, December 1993.
29. D'allens H, Richard A, Bertin L, et al. Responsiveness assessment of a specific quality of life questionnaire for migraineurs (QVM). Qual Life Res 1994;3:72.
30. Scopp AL, Peters KS. Patient rating of trigger elimination effectiveness in comprehensive migraine treatment program [abstract]. Headache 1992;32:269.
31. VandenBree MB, Passchier J, Emmen HH. Influence of quality of life and stress coping behaviour on headaches in adolescent male students: an explorative study. Headache 1990;30: 165-168.
32. Solomon GD, Litaker DG, Genzen JR. Use of the SF-36 to predict response to sumatriptan in migraine patients. Drug Inf J 1996;30 (in press).
33. Barnat MR, Lake AK. Patient attitudes about headache. Headache 1983;23:229-237.